Sorafenib

Mechanism of action

Sorafenib is a protein kinase inhibitor with activity against many protein kinases, including VEGFR, PDGFR and RAF kinases. (See BRAF (gene)#Sorafenib for details the drug's interaction with B-Raf.)

Sorafenib treatment induces autophagy, which may suppress tumor growth. Based on its 1,3-disubstituted urea structure, sorafenib is also a potent soluble epoxide hydrolase inhibitor and this activity likely reduces the severity of its adverse effects.

Medical uses

Sorafenib is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC), thyroid cancer and Acute Myeloid Leukaemia with FLT3-ITD mutation..

Kidney cancer

Clinical trial results, published January 2007, showed that, compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear cell renal cell carcinoma in whom previous therapy has failed. The median progression-free survival was 5.5 months in the sorafenib group and 2.8 months in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55; P

In Australia this is one of two TGA-labelled indications for sorafenib, although it is not listed on the Pharmaceutical Benefits Scheme for this indication.

Liver cancer

At ASCO 2007, results from the SHARP trial were presented, which showed efficacy of sorafenib in hepatocellular carcinoma. The primary endpoint was median overall survival, which showed a 44% improvement in patients who received sorafenib compared to placebo (hazard ratio 0.69; 95% CI, 0.55 to 0.87; p=0.0001). Both median survival and time to progression showed 3-month improvements; however, there was no significant difference in median time to symptomatic progression (p=0.77). There was no difference in quality of life measures, possibly attributable to toxicity of sorafenib or symptoms related to underlying progression of liver disease. Of note, this trial only included patients with Child-Pugh Class A (i.e. mildest) cirrhosis. Because of this trial sorafenib obtained FDA approval for the treatment of advanced hepatocellular carcinoma in November 2007.

In a randomized, double-blind, phase II trial combining sorafenib with doxorubicin, the median time to progression was not significantly delayed compared with doxorubicin alone in patients with advanced hepatocellular carcinoma. Median durations of overall survival and progression-free survival were significantly longer in patients receiving sorafenib plus doxorubicin than in those receiving doxorubicin alone.

A prospective single-centre phase II study which included the patients with unresectable hepatocellular carcinoma (HCC) concluding that the combination of sorafenib and DEB-TACE in patients with unresectable HCC is well tolerated and safe, with most toxicities related to sorafenib.

In Australia this is the only indication for which sorafenib is listed on the PBS and hence the only government-subsidised indication for sorafenib. Along with renal cell carcinoma, hepatocellular carcinoma is one of the TGA-labelled indications for sorafenib.

Thyroid cancer

On 22 November 2013, sorafenib was approved by the FDA for the treatment of locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.

The phase III DECISION trial showed significant improvement in progression-free survival but not in overall survival. However, as is known, the side effects were very frequent, specially hand and foot skin reaction.

Acute Myeloid Leukaemia

In patients with FLT3-ITD mutated AML, sorafenib can be used as a maintenance therapy post-Allogeneic haematopoietic stem-cell transplantation to target any residual disease that could remain in the bone marrow.

Adverse effects

Adverse effects by frequency

Note: Potentially serious side effects are in bold.

Very common (10% frequency)

• Lymphopenia
• HypophosphataemiaLow blood phosphate levels
• HaemorrhageBleeding; including serious bleeds such as intracranial and intrapulmonary bleeds
• HypertensionHigh blood pressure
• Diarrhea
• Rash
• Alopecia (hair loss; occurs in roughly 30% of patients receiving sorafenib)
• Hand-foot syndrome
• Pruritus (itchiness)
• Erythema
• Increased amylase
• Increased lipase
• Fatigue
• PainIncluding abdominal pain, headache, tumour pain, etc.
• Nausea
• VomitingConsidered a low (~10-30%) risk chemotherapeutic agent for causing emesis)

Common (1-10% frequency)

• LeucopeniaLow level of white blood cells in the blood
• NeutropoeniaLow level of neutrophils in the blood
• AnaemiaLow level of red blood cells in the blood
• ThrombocytopeniaLow level of plasma cells in the blood
• Anorexia (weight loss)
• HypocalcaemiaLow blood calcium
• HypokalaemiaLow blood potassium
• Depression
• Peripheral sensory neuropathy
• TinnitusHearing ringing in the ears
• Congestive heart failure
• Myocardial infarctionHeart attack
• Myocardial ischaemiaLack of blood supply for the heart muscle
• Hoarseness
• Constipation
• StomatitisMouth swelling, also dry mouth and glossodynia
• DyspepsiaIndigestion
• DysphagiaNot being able to swallow
• Dry skin
• Exfoliative dermatitis
• Acne
• Skin desquamation
• ArthralgiaSore joints
• MyalgiaMuscle aches
• Kidney failureKidney failure
• ProteinuriaExcreting protein [usually plasma proteins] in the urine. Not dangerous in itself but it is indicative kidney damage
• Erectile dysfunction
• Asthenia (weakness)
• Fever
• Influenza-like illness
• Transient increase in transaminase

Uncommon (0.1-1% frequency)

• Folliculitis
• Infection
• Hypersensitivity reactionsIncluding skin reactions and urticaria (hives)
• HypothyroidismUnderactive thyroid
• HyperthyroidismOveractive thyroid
• HyponatraemiaLow blood sodium
• Dehydration
• Reversible posterior leukoencephalopathy
• Hypertensive crisis
• RhinorrhoeaRunny nose
• Interstitial lung disease-like eventsPneumonitis, radiation pneumonitis, acute respiratory distress, etc.
• Gastro-oesophageal reflux disease (GORD)
• PancreatitisSwelling of the pancreas
• GastritisSwelling of the stomach
• Gastrointestinal perforationsFormation of a hole in the gastrointestinal tract, leading to potentially fatal bleeds
• Increase in bilirubin leading, potentially, to jaundiceYellowing of the skin and eyes due to a failure of the liver to adequately cope with the amount of bilirubin produced by the day-to-day actions of the body
• CholecystitisSwelling of the gallbladder
• CholangitisSwelling of the bile duct
• Eczema
• Erythema multiformeA potentially fatal skin reaction
• KeratoacanthomaA fairly benign form of skin cancer
• Squamous cell carcinoma
• Gynaecomastia (swelling of the breast tissue in men)
• Transient increase in blood alkaline phosphatase
• INR abnormal
• Prothrombin level abnormal
• bulbous skin reaction

Rare (0.01-0.1% frequency)

• QT interval prolongationA potentially fatal abnormality in the electrical activity of the heart
• AngiooedemaSwelling of the skin and mucous membranes
• Anaphylactic reactionA potentially fatal allergic reaction
• HepatitisSwelling of the liver
• Radiation recall dermatitis
• Stevens–Johnson syndrome
• Leucocytoclastic vasculitis
• Toxic epidermal necrolysis
• Nephrotic syndrome
• RhabdomyolysisThe rapid breakdown of muscle tissue leading to the build-up of myoglobin in the blood and resulting in damage to the kidneys

History

Renal cancer

Sorafenib was approved by the U.S. Food and Drug Administration (FDA) in December 2005, and received European Commission marketing authorization in July 2006, both for use in the treatment of advanced renal cancer.

Liver cancer

The European Commission granted marketing authorization to the drug for the treatment of patients with hepatocellular carcinoma(HCC), the most common form of liver cancer, in October 2007, and FDA approval for this indication followed in November 2007.

In November 2009, the UK's National Institute for Clinical Excellence declined to approve the drug for use within the NHS in England, Wales and Northern Ireland, stating that its effectiveness (increasing survival in primary liver cancer by 6 months) did not justify its high price, at up to £3000 per patient per month. In Scotland the drug had already been refused authorization by the Scottish Medicines Consortium for use within NHS Scotland, for the same reason.

In March 2012, the Indian Patent Office granted a domestic company, Natco Pharma, a license to manufacture generic sorafenib, bringing its price down by 97%. Bayer sells a month's supply, 120 tablets, of Nexavar for. Natco Pharma will sell 120 tablets for , while still paying a 6% royalty to Bayer. The royalty was later raised to 7% on appeal by Bayer. Under the Patents Act, 1970 and the World Trade Organisation TRIPS Agreement, the government can issue a compulsory license when a drug is not available at an affordable price.

Society and culture

Nexavar controversy

In January 2014, Bayer's CEO Marijn Dekkers allegedly stated that Nexavar was developed for "Western patients who can afford it, not for Indians". A kidney cancer patient would pay $96,000 (£58,000) for a year's course of the Bayer-made drug, whereas the cost of the Indian version of the generic drug would be around $2,800 (£1,700).

Research

Lung

In some kinds of lung cancer (with squamous-cell histology) sorafenib administered in addition to paclitaxel and carboplatin may be detrimental to patients.

Ovarian cancer

Sorafenib has been studied as maintenance therapy after ovarian cancer treatment and in combination with chemotherapy for recurrent ovarian cancer but did not show results that led to approval of the drug for these indications.

Brain (recurrent glioblastoma)

There is a phase I/II study at the Mayo Clinic of sorafenib and CCI-779 (temsirolimus) for recurrent glioblastoma.

Desmoid tumor (aggressive fibromatosis)

A study performed in 2008 showed that sorafenib is active against aggressive fibromatosis. This study is being used as justification for using sorafenib as an initial course of treatment in some patients with the condition.

A phase III clinical trial is testing the effectiveness of sorafenib to treat desmoid tumors (also known as aggressive fibromatosis), after positive results in the first two trial stages. Dosage is typically half of that applied for malignant cancers (400 mg vs 800 mg). NCI are sponsoring this trial.

Notes

References

References

1. (17 September 2018). "Nexavar EPAR".
2. (19 November 2007). "FDA Approves Nexavar for Patients with Inoperable Liver Cancer". FDA.
3. (October 2008). "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling". Molecular Cancer Therapeutics.
4. (January 2009). "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations". Oncogene.
5. (January 2014). "Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways". Molecular Medicine Reports.
6. (30 March 2020). "Encyclopedia of Molecular Pharmacology". Springer, Cham.
7. "Nexavar (sorafenib) dosing, indications, interactions, adverse effects, and more". WebMD.
8. (November 2013). "Nexavar (sorafenib) tablet, film coated [Bayer HealthCare Pharmaceuticals Inc.]". Bayer HealthCare Pharmaceuticals Inc..
9. (27 March 2013). "Nexavar 200mg film-coated tablets - Summary of Product Characteristics (SPC) - (eMC)". Bayer plc.
10. (12 December 2012). "PRODUCT INFORMATION NEXAVAR (sorafenib tosylate)". Bayer Australia Ltd.
11. (January 2007). "Sorafenib in advanced clear-cell renal-cell carcinoma". The New England Journal of Medicine.
12. (July 2008). "Sorafenib in advanced hepatocellular carcinoma". The New England Journal of Medicine.
13. (2009). "Sorafenib: a review of its use in advanced hepatocellular carcinoma". Drugs.
14. (October 2011). "Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma". Journal of Clinical Oncology.
15. "Pharmaceutical Benefits Scheme (PBS) -SORAFENIB". Australian Government Department of Health.
16. (5 October 2006). "FDA Approval for Sorafenib Tosylate".
17. (4 June 2013). "ASCO: Sorafenib Halts Resistant Thyroid Cancer".
18. (29 July 2020). "Data Show Sorafenib Maintenance Therapy After Allo-HSCT Improves Outcomes in FLT3-ITD-Positive AML".
19. (3 July 2012). "Chemotherapy-Induced Nausea and Vomiting Treatment & Management". WebMD.
20. (August 2010). "Unusually Severe Bullous Skin Reaction to Sorafenib: A Case Report". Journal of Medical Cases.
21. "FDA Approval letter for use of sorafenib in advanced renal cancer".
22. "Nexavar". [[European Commission]].
23. (30 October 2007). "Nexavar (Sorafenib) Approved for Hepatocellular Carcinoma in Europe". Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals.
24. "FDA Approval letter for use of sorafenib in inoperable hepatocellular carcinoma".
25. (19 November 2009). "Liver drug 'too expensive'". BBC News.
26. "» Supreme Court says no to Bayer, upholds compulsory license on Nexavar".
27. "Application for Compulsory Licence Under Section 84(1) of the Patents Act, 1970 in Respect of Patent No.215758". Controller of Patents Mumbai.
28. (9–15 March 2012). "Indian generics". Nature.
29. "India Patents (Amendment) Act, 2005". WIPO.
30. (29 January 2014). "Bloomberg's viral misquote". Columbia Journalism Review.
31. (April 25, 2008). "Addition of Sorafenib May Be Detrimental in Some Lung Cancer Patients". MedScape.
32. (July 2016). "Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature". Expert Opinion on Investigational Drugs.
33. {{ClinicalTrialsGov. NCT00329719. Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
34. (June 2011). "Activity of Sorafenib against desmoid tumor/deep fibromatosis". Clinical Cancer Research.
35. "Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis".
36. (June 2011). "Activity of Sorafenib against desmoid tumor/deep fibromatosis". Clinical Cancer Research.
37. (February 2024). "Desmoid Tumors: Current Perspective and Treatment". Current Treatment Options in Oncology.